| Ms Jerelyn Renae Reeves, LPN | |
|
649 Chenango St Apt 1, Binghamton, NY 13901-2061 | |
| (607) 349-5841 | |
| Not Available |
| Full Name | Ms Jerelyn Renae Reeves |
|---|---|
| Gender | Female |
| Speciality | Licensed Vocational Nurse |
| Location | 649 Chenango St Apt 1, Binghamton, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669947438 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164X00000X | Licensed Vocational Nurse | 330068-1 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Jerelyn Renae Reeves, LPN 649 Chenango St Apt 1, Binghamton, NY 13901-2061 Ph: (607) 349-5841 | Ms Jerelyn Renae Reeves, LPN 649 Chenango St Apt 1, Binghamton, NY 13901-2061 Ph: (607) 349-5841 |
News Archive
The US Army, through the Telemedicine and Advanced Technology Research Center (TATRC), has awarded Energid Technologies a contract to develop a robotic approach to airway management.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the publication of new data in the journal Nature Biotechnology by Alnylam scientists and collaborators from Tekmira Pharmaceuticals Corporation, AlCana Technologies, Inc., and The University of British Columbia (UBC). The new study employed a rational design approach for the discovery of novel lipids that can be incorporated into lipid nanoparticles (LNPs) for systemic delivery of RNAi therapeutics.
There are only two FDA/EMEA approved drugs currently available for treating advanced melanoma. The available drugs, however, are not completely effective and have adverse effects. Unmet needs of patients, especially those with advanced melanoma are therefore quite high and have led to a low drug adoption and market growth over the years. The future looks brighter though, with a few promising drugs in pipeline for advanced melanoma.
Future Science Group today announced the publication of a new article in Future Science OA examining the effects of diabetes on hospitalization risk, chances of multiple admissions, and length of hospitalization stay, for patients suffering from solid-organ malignancies such as breast, colorectal, lung and pancreas, among others.
Researchers at King's College London and the Wellcome Trust Sanger Institute in the United Kingdom have for the first time demonstrated a direct link between the Wbp2 gene and progressive hearing loss. The scientists report that the loss of Wbp2 expression leads to progressive high-frequency hearing loss in mouse as well as in two clinical cases of children with deafness with no other obvious features.
› Verified 3 days ago